Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.05 from other evidence | 0.00 |
| cell type Human Protein Atlas | enriched in the midbrain (3 nTPM), where the nigral dopamine neurons sit | 0.90 |
| chemistry Open Targets | compounds already reach it: camrelizumab, dostarlimab, finotonlimab +23 | 0.90 |
| trials ClinicalTrials.gov | 127 Parkinson's trials, 6 stopped | 0.90 |
| literature PubMed | 2 Parkinson's papers of 1,208 | 0.85 |
| pathways Reactome | 3 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 5150
Sealed predictions
- PDCD1 in dopamine neurons, braak-0.41 (p 0.273) → -0.57 (p 0.111)receipt 5157
Swarm cases
receipt 5157: PDCD1 in dopamine neurons, braak
- power
- full sample -0.47 (p 0.047, n 18), 95% CI -0.77 to -0.01. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.42 (p 0.082, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.51 (p 0.029, n 18). not the mix.
- skeptic
- leave-one-out range -0.60 to -0.40, sign flips 0; without severely affected donors -0.47 (p 0.047, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PDCD1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts